ArticleCancer immunology, immunotherapy : CII2006
Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes.
Article in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
203 citing papers in PubMed, 1 synthesis or guideline pooled it, 387 citations in OpenAlex.
- Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles.Journal of extracellular vesicles · 2021Guideline
- METTL3 regulates exocytosis independently of mScience advances · 2026Article
- Mechanisms and functions of large extracellular vesicle biogenesis.Nature cell biology · 2026Review
- The Dual Role of Extracellular Vesicles in Aging and Age-Related Diseases: Pathophysiology and Therapeutic Potential.International journal of nanomedicine · 2026Review
- Stability Dynamics of Plant-Based Extracellular Vesicles Drug Delivery.Journal of xenobiotics · 2025Review
- Liquid biopsies in cancer.Molecular biomedicine · 2025Review
- Characterization of extracellular vesicles released fromPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Effect of Kinases in Extracellular Vesicles from HIV-1-Infected Cells on Bystander Cells.Cells · 2025Article
- Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances.Frontiers in immunology · 2025Review
- Relationship between exosomes and cancer: formation, diagnosis, and treatment.International journal of biological sciences · 2025Review
- Identification of miRNAs Present in Cell- and Plasma-Derived Extracellular Vesicles-Possible Biomarkers of Colorectal Cancer.Cancers · 2024Article
- Decoding bioactive signals of the RNA secretome: the cell-free messenger RNA catalogue.Expert reviews in molecular medicine · 2024Review
- Oxidative stress-induced changes in the transcriptomic profile of extracellular vesicles.Journal of extracellular biology · 2024Article
- Topographic Distribution of miRNAs (miR-30a, miR-223, miR-let-7a, miR-let-7f, miR-451, and miR-486) in the Plasma Extracellular Vesicles.Non-coding RNA · 2024Article
- Extracellular vesicle-mediated communication between CD8Frontiers in immunology · 2024Review
- G protein-coupled receptors: a gateway to targeting oncogenic EVs?Extracellular vesicles and circulating nucleic acids · 2024Review
- Exosomal lncRNAs as regulators of breast cancer chemoresistance and metastasis and their potential use as biomarkers.Frontiers in oncology · 2024Review
- CD44‑hyaluronan axis plays a role in the interactions between colon cancer‑derived extracellular vesicles and human monocytes.Oncology letters · 2023Article
- Article
- Horizontal Transfer of Malignant Traits and the Involvement of Extracellular Vesicles in Metastasis.Cells · 2023Review
143 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to determine the characteristics of tumour cell-derived microvesicles (TMV) and their interactions with human monocytes. TMV were shed spontaneously by three different human cancer cell lines but their release was significantly increased upon activation of the cells with phorbol 12-myristate 13-acetate (PMA). TMV showed the presence of several surface determinants of tumour cells, e.g. HLA class I, CD29, CD44v7/8, CD51, chemokine receptors (CCR6, CX3CR1), extracellular matrix metalloproteinase inducer (EMMPRIN), epithelial cell adhesion molecule (EpCAM), but their level of expression differed from that on cells they originated from. TMV also carried mRNA for growth factors: vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), interleukin-8 (IL-8) and surface determinants (CD44H). TMV were localized at the monocytes surface following their short exposure to TMV, while at later times intracellularly. TMV transferred CCR6 and CD44v7/8 to monocytes, exerted antiapoptotic effect on monocytes and activated AKT kinase (Protein Kinase B). Thus, TMV interact with monocytes, alter their immunophenotype and biological activity. This implicates the novel mechanism by which tumour infiltrating macrophages may be affected by tumour cells not only by a direct cell to cell contact, soluble factors but also by TMV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.